A detailed history of Manufacturers Life Insurance Company, The transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Manufacturers Life Insurance Company, The holds 26,038 shares of SUPN stock, worth $940,492. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,038
Previous 26,554 1.94%
Holding current value
$940,492
Previous $710,000 14.23%
% of portfolio
0.0%
Previous 0.0%

Shares

33 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$25.77 - $35.16 $13,297 - $18,142
-516 Reduced 1.94%
26,038 $811,000
Q2 2024

Aug 14, 2024

BUY
$25.99 - $33.85 $48,601 - $63,299
1,870 Added 7.58%
26,554 $710,000
Q1 2024

May 14, 2024

SELL
$27.11 - $35.17 $6,181 - $8,018
-228 Reduced 0.92%
24,684 $841,000
Q4 2023

Feb 13, 2024

SELL
$22.72 - $29.68 $20,016 - $26,148
-881 Reduced 3.42%
24,912 $720,000
Q3 2023

Nov 15, 2023

BUY
$27.57 - $32.91 $155,246 - $185,316
5,631 Added 27.93%
25,793 $711,000
Q2 2023

Aug 11, 2023

BUY
$29.91 - $38.73 $12,741 - $16,498
426 Added 2.16%
20,162 $606,000
Q1 2023

May 15, 2023

BUY
$34.93 - $42.03 $3,178 - $3,824
91 Added 0.46%
19,827 $718,000
Q4 2022

Aug 11, 2023

BUY
$31.09 - $37.88 $7,150 - $8,712
230 Added 1.18%
19,736 $703,000
Q4 2022

Feb 13, 2023

BUY
$31.09 - $37.88 $7,150 - $8,712
230 Added 1.18%
19,736 $703,000
Q3 2022

Aug 11, 2023

SELL
$28.79 - $35.41 $9,356 - $11,508
-325 Reduced 1.64%
19,506 $660,000
Q3 2022

Nov 03, 2022

SELL
$28.79 - $35.41 $9,356 - $11,508
-325 Reduced 1.64%
19,506 $660,000
Q2 2022

Aug 11, 2023

SELL
$25.33 - $34.25 $10,283 - $13,905
-406 Reduced 2.01%
19,831 $573,000
Q2 2022

Aug 15, 2022

SELL
$25.33 - $34.25 $10,283 - $13,905
-406 Reduced 2.01%
19,831 $574,000
Q1 2022

Aug 11, 2023

BUY
$28.51 - $32.9 $11,689 - $13,489
410 Added 2.07%
20,237 $654,000
Q1 2022

May 20, 2022

SELL
$28.51 - $32.9 $138,929 - $160,321
-4,873 Reduced 19.41%
20,237 $654,000
Q4 2021

Feb 16, 2022

SELL
$26.37 - $34.22 $18,195 - $23,611
-690 Reduced 2.67%
25,110 $732,000
Q3 2021

Nov 12, 2021

SELL
$23.54 - $31.39 $45,408 - $60,551
-1,929 Reduced 6.96%
25,800 $688,000
Q2 2021

Aug 12, 2021

SELL
$26.72 - $33.19 $3,473 - $4,314
-130 Reduced 0.47%
27,729 $854,000
Q1 2021

May 03, 2021

SELL
$24.15 - $31.45 $42,165 - $54,911
-1,746 Reduced 5.9%
27,859 $729,000
Q4 2020

Feb 12, 2021

BUY
$17.7 - $25.81 $12,974 - $18,918
733 Added 2.54%
29,605 $745,000
Q3 2020

Nov 09, 2020

SELL
$20.2 - $25.05 $9,372 - $11,623
-464 Reduced 1.58%
28,872 $602,000
Q2 2020

Aug 10, 2020

SELL
$17.09 - $24.89 $39,836 - $58,018
-2,331 Reduced 7.36%
29,336 $683,000
Q1 2020

May 15, 2020

BUY
$14.45 - $24.69 $26,226 - $44,812
1,815 Added 6.08%
31,667 $570,000
Q4 2019

Feb 14, 2020

SELL
$19.93 - $29.13 $16,342 - $23,886
-820 Reduced 2.67%
29,852 $708,000
Q3 2019

Nov 12, 2019

SELL
$25.47 - $33.37 $9,220 - $12,079
-362 Reduced 1.17%
30,672 $843,000
Q2 2019

Aug 14, 2019

SELL
$29.96 - $38.87 $34,244 - $44,428
-1,143 Reduced 3.55%
31,034 $1.03 Million
Q1 2019

May 13, 2019

BUY
$32.77 - $41.99 $64,687 - $82,888
1,974 Added 6.54%
32,177 $1.13 Million
Q4 2018

Feb 14, 2019

SELL
$30.84 - $49.51 $54,000 - $86,692
-1,751 Reduced 5.48%
30,203 $1 Million
Q3 2018

Nov 14, 2018

SELL
$42.7 - $56.55 $194,370 - $257,415
-4,552 Reduced 12.47%
31,954 $1.61 Million
Q2 2018

Aug 14, 2018

BUY
$44.1 - $59.85 $14,994 - $20,349
340 Added 0.94%
36,506 $2.18 Million
Q1 2018

May 15, 2018

SELL
$37.15 - $46.9 $31,688 - $40,005
-853 Reduced 2.3%
36,166 $1.66 Million
Q4 2017

Feb 08, 2018

BUY
$36.4 - $42.6 $32,905 - $38,510
904 Added 2.5%
37,019 $1.48 Million
Q3 2017

Nov 14, 2017

BUY
$36.75 - $49.65 $1.33 Million - $1.79 Million
36,115
36,115 $1.45 Million

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.93B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Manufacturers Life Insurance Company, The Portfolio

Follow Manufacturers Life Insurance Company, The and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

News

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.